Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27815142 | 0.90 | HTR2A (0.43) | SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL27610705 | 0.89 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3HTR2CHTR1A | |
| SCHEMBL9483225 | 0.84 | HTR2C (0.51) | HTR2C | |
| SCHEMBL20840816 | 0.83 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HTR2CHTR1A | |
| SCHEMBL14938104 | 0.83 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR2CHTR1A | |
| SCHEMBL6641568 | 0.83 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR2CHTR1A | |
| SCHEMBL11498275 | 0.80 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3HTR2CHTR1A | |
| SCHEMBL5450499 | 0.79 | PNMT (0.43) | SLC6A2SLC6A4SLC6A3HTR2CHTR1A | |
| Hydrochloric Acid SCHEMBL11198045 | 0.79 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR2CHTR1A | |
| SCHEMBL28533805 | 0.77 | HTR2C (0.57) | SLC6A2SLC6A4SLC6A3HTR2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104470918-A | Aromatic heterocyclic derivative and pharmaceutical | NIPPON SHINYAKU CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-8349836-B2 | Phthalazine derivatives as inhibitors of protein kinase | ARALDI GIAN-LUCA (US) | 2013-01-08 | — | — | US | disclosed |
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | disclosed |
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | ARALDI GIAN-LUCA | 2011-09-29 | — | — | US | disclosed |
| EP-2131656-A2 | PHTHALAZINE DERIVATIVES | Forest Laboratories Holdings Limited (BM) | 2009-12-16 | — | — | EP | disclosed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | disclosed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
| US-5622966-A | BACTERICIDES TREATING INFECTIONS | WARNER-LAMBERT COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5446044-A | Bactericides | WARNER-LAMBERT COMPANY (US) | 1995-08-29 | — | — | US | disclosed |
| US-5384407-A | Pyrrolidine compounds | WARNER-LAMBERT COMPANY (US) | 1995-01-24 | — | — | US | disclosed |
| US-5342844-A | 7-substituted quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| WO-1993016077-A1 | 7-SUBSTITUTED QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-08-19 | — | — | WO | disclosed |
| US-5221676-A | 7-substituted quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1993-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | SLC6A2 4151/4885SLC6A4 4237/4885SLC6A3 3754/4885 |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | SLC6A2 4151/4885SLC6A4 4237/4885SLC6A3 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.